Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 16, 2012, Pages 6211-6216

  Santi, Daniel V ^a   Schneider, Eric L ^a   Reid, Ralph ^a   Robinson, Louise ^a   Ashley, Gary W ^a  

^a ProLynx   (United States)

Author keywords

Implant; Metronomic chemotherapy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKENYL GROUP; AMINE; BETA ALKENYL SULFONE; CARBAMIC ACID; EXATECAN; EXENDIN 4; FUMAGILLOL; SUCCINIMIDE DERIVATIVE; SUCCINIMIDYL CARBONATE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANIMALS; CARBONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; HALF-LIFE; HYPOGLYCEMIC AGENTS; KINETICS; MACROMOLECULAR SUBSTANCES; MALE; MICE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PEPTIDES; POLYETHYLENE GLYCOLS; PRODRUGS; RATS, SPRAGUE-DAWLEY; SUCCINIMIDES; VENOMS;

EID: 84860012591     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117147109     Document Type: Article

References (24)

1. Alconcel SNS, Baas AS, Maynard HD (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem 2:1442-1448.
2. Fishburn CS (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 97:4167-4183.
3. Filpula D, Zhao H (2008) Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 60:29-49. (Pubitemid 350181165)
4. Greenwald RB, Choe YH, McGuire J, Conover CD (2003) Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55:217-250. (Pubitemid 36135917)
5. Marcus Y, Sasson K, Fridkin M, Shechter Y (2008) Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: A study with gentamicin. J Med Chem 51:4300-4305. (Pubitemid 352032454)
6. Peleg-Shulman T, et al. (2004) Reversible PEGylation: A novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 47:4897-4904. (Pubitemid 39238265)
7. Wolfe NL, Zepp RG, Paris DF (1978) Use of structure-reactivity relationships to estimate hydrolytic persistence of carbamate pesticides. Water Res 12:561-563. (Pubitemid 8392055)
8. Christenson I (1964) Alkaline hydrolysis of some carbamic acid esters. Acta Chem Scand 18:904-922.
9. Marshall DR, Thomas PJ, Stirling CJM (1977) Elimination and addition reactions. Part 32. Discrimination between concerted and stepwise processes in activated elimination reactions. J Chem Soc, Perkin Trans 2:1914-1919.
10. Debets MF, et al. (2010) Aza-dibenzocyclooctynes for fast and efficient enzyme PE-Gylation via copper-free (3+2) cycloaddition. Chem Commun (Camb) 46:97-99.
11. Hughes WL, Dintzis HM (1964) Crystallization of the mercury dimers of human and bovine mercaptalbumin. J Biol Chem 239:845-849.
12. Friedman M, Cavins JF, Wall JS (1965) Relative nucleophilic reactivities of amino groups and mercaptide ions in addition reactions with α,β-unsaturated compounds. J Am Chem Soc 87:3672-3682.
13. Soepenberg O, et al. (2005) Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 11:703-711. (Pubitemid 40116898)
14. Walsh MD, et al. (2012) Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res, PMID:22392910 [ePub ahead of print].
15. Schluep T, Cheng J, Khin KT, Davis ME (2006) Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 57:654-662. (Pubitemid 43237851)
16. Patnaik A, et al. (2008) Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients with advanced malignancies: A phase I dose-escalation study. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 23, 2008 Poster No 427.
17. Yurkovetskiy A, et al. (2009) Pharmacokinetics of a novel fumagillol conjugate XMT- 1107 in the rat. AACR Meeting Abstracts, April, 2009; 2009:1572 (abstract).
18. Hanai T, Koizumi K, Kinoshita T, Arora R, Ahmed F (1997) Prediction of pKa values of phenolic and nitrogen-containing compounds by computational chemical analysis compared to those measured by liquid chromatography. J Chromatogr A 762:55-61. (Pubitemid 27122818)
19. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269.
20. Madsbad S, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394-407.
21. Gao W, Jusko WJ (2011) Pharmacokinetic and pharmacodynamic modeling of exendin- 4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 336:881-890.
22. Drucker DJ, et al.; DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372:1240-1250.
23. Kim D, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493. (Pubitemid 46871159)
24. Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 7:455-465.